Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

This article was originally published in PharmAsia News

Executive Summary

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Advertisement

Related Content

Merck Eyes Emerging Biosimilars Market In Japan
Japan Favors 'Bio-betters' Over Biosimilars
Merck Eyes Emerging Biosimilars Market In Japan
Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition
Nippon Chemiphar Parts Ways With Ranbaxy; Takes Over Generics Venture
Nippon Chemiphar Parts Ways With Ranbaxy, Takes Over Generics Venture
As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets
MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
Advertisement
UsernamePublicRestriction

Register

SC070255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel